Acadia drops after hours on Phase III miss for schizophrenia

Acadia drops after hours on Phase III miss for schizophrenia

Source: 
BioCentury
snippet: 

Acadia shed $3.96 (15%) to $22.01 in after hours trading Monday when it reported after market close that Nuplazid pimavanserin as an adjunct schizophrenia therapy missed the primary endpoint and key secondary endpoint in the Phase III ENHANCE trial.